Himal Lal

发表

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial

L. Cámpora, T. Mrkvan, C. Hervé, 2018, Open Forum Infectious Diseases.

Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.

L. Cámpora, M. Levin, Robert W. Johnson, 2018, Vaccine.

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

K. Jansen, W. Gruber, I. Scully, 2021, Human vaccines & immunotherapeutics.

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Shinn-Jang Hwang, M. Levin, T. Vesikari, 2015, The New England journal of medicine.

Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.

J. Richardus, T. Schwarz, L. Rombo, 2016, Vaccine.

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

K. Jansen, W. Gruber, I. Scully, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

H. Ikematsu, Shinn-Jang Hwang, M. Levin, 2018, The Journal of infectious diseases.

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine

L. Cámpora, I. Vastiau, T. Heineman, 2017, The Journal of infectious diseases.

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

L. Cámpora, Martina Kovac, T. Heineman, 2017, Human vaccines & immunotherapeutics.

Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly

T. Heineman, M. Shiramoto, M. Eda, 2016, Human vaccines & immunotherapeutics.

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su)

T. Heineman, T. Zahaf, Himal Lal, 2013, Human vaccines & immunotherapeutics.

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

H. Ikematsu, Shinn-Jang Hwang, T. Mrkvan, 2019, Human vaccines & immunotherapeutics.

Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

Shinn-Jang Hwang, L. Cámpora, E. Ledent, 2019, Vaccine.

Safety proﬁle of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials q

Berglund, L. Cámpora, E. Ledent, 2019 .

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older

T. Schwarz, T. Heineman, L. Oostvogels, 2017, The Journal of infectious diseases.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Lidia Oostvogels, Jan Smetana, Daisuke Watanabe, 2016, The New England journal of medicine.

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

L. Cámpora, M. Levin, Robert W. Johnson, 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.

L. Cámpora, B. Geeraerts, T. Heineman, 2018, Vaccine.

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

J. Richardus, T. Schwarz, G. Sonder, 2018, Human vaccines & immunotherapeutics.

A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.

P. van Damme, G. Leroux-Roels, I. Vastiau, 2017, Vaccine.

The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.

L. Cámpora, T. Heineman, A. Schuind, 2019, Vaccine.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.

C. Hervé, T. Heineman, L. Oostvogels, 2018, Vaccine.

Persistence of the Immune Response to an Adjuvanted Herpes Zoster Subunit Vaccine in Healthy Older Adults: Modeling of Vaccine-Induced Immune Response, Data From a 6-Year Follow-Up Study

J. Richardus, T. Schwarz, T. Heineman, 2015 .

Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies

Shinn-Jang Hwang, L. Cámpora, M. Levin, 2016 .

Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage.

D. Landman, J. Quale, V. Manikal, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunogenicity and Safety of 2 Doses of an Investigational Herpes Zoster Subunit Vaccine Administered 2, 6 or 12 Months Apart in Adults 50 Years and Older: Results of a Phase III, Randomized, Open-Label, Multicenter Trial

B. Geeraerts, T. Heineman, L. Oostvogels, 2016 .

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

L. Cámpora, M. Levin, Robert W. Johnson, 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.